ProQR Therapeutics N.V. Forecast, price target & analysts
ProQR Therapeutics N.V. Target price 2026 - Analyst rating & recommendation
ProQR Therapeutics N.V. Classifications & Recommendation
ProQR Therapeutics N.V. Price Target
| Target Price | $8.67 |
| Price | $1.65 |
| Potential |
425.46%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target ProQR Therapeutics N.V. 2027 .
The average ProQR Therapeutics N.V. target price is $8.67.
This is
425.46%
register free of charge
$15.75
854.55%
register free of charge
$3.03
83.64%
register free of charge
|
|
| A rating was issued by 16 analysts: 15 Analysts recommend ProQR Therapeutics N.V. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ProQR Therapeutics N.V. stock has an average upside potential 2027 of
425.46%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 18.58 | 21.08 |
| 16.38% | 13.46% | |
| EBITDA Margin | -251.51% | -338.29% |
| 77.41% | 34.51% | |
| Net Margin | -258.13% | -323.83% |
| 81.74% | 25.45% |
10 Analysts have issued a sales forecast ProQR Therapeutics N.V. 2026 . The average ProQR Therapeutics N.V. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an ProQR Therapeutics N.V. EBITDA forecast 2026. The average ProQR Therapeutics N.V. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 ProQR Therapeutics N.V. Analysts have issued a net profit forecast 2026. The average ProQR Therapeutics N.V. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.46 | -0.48 |
| 24.32% | 4.35% | |
| P/E | negative | |
| EV/Sales | 5.32 |
10 Analysts have issued a ProQR Therapeutics N.V. forecast for earnings per share. The average ProQR Therapeutics N.V. EPS is
This results in the following potential growth metrics and future valuations:
ProQR Therapeutics N.V....
Current ProQR Therapeutics N.V. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B of A Securities |
Locked
➜
Locked
|
Locked | Aug 20 2026 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Jun 29 2026 |
| Jones Trading |
Locked
➜
Locked
|
Locked | Jun 26 2026 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Jun 26 2026 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Apr 09 2026 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Nov 04 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
B of A Securities:
Locked
➜
Locked
|
Aug 20 2026 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Jun 29 2026 |
|
Locked
Jones Trading:
Locked
➜
Locked
|
Jun 26 2026 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Jun 26 2026 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Apr 09 2026 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Nov 04 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 08 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
